SCHEMBL25596204

SCHEMBL25596204

Cc1ccc(C(F)C(C)(N)C(=O)O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
LMNA P02545 5/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
POLB P06746 1/20 0.39
ALOX5 P09917 1/20 0.39
HPGD P15428 2/20 0.37
KEAP1 Q14145 3/20 0.36
NFE2L2 Q16236 3/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
CYP2C19 P33261 2/20 0.36
CHRNA7 P36544 1/20 0.35
ACHE P22303 1/20 0.35
PKM P14618 2/20 0.34
HTT P42858 2/20 0.34
ATM Q13315 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
NLRP1 Q9C000 1/20 0.34
MEN1 O00255 1/20 0.34
NTSR1 P30989 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22074702 0.86 BLM (0.46) ALDH1A1LMNACYP2C19
SCHEMBL6438147 0.85 CYP2C19 (0.44) LMNAALOX5CYP2C19HTTATM
SCHEMBL30722430 0.80 ALOX5 (0.43) ALDH1A1LMNASMN1; SMN2ALOX5KEAP1
SCHEMBL25369463 0.72 KEAP1 (0.39) ALDH1A1LMNASMN1; SMN2POLBALOX5
SCHEMBL28761408 0.69 ACHE (0.47) ALDH1A1LMNASMN1; SMN2POLBALOX5
SCHEMBL6533964 0.69 GAA (0.43) CYP2C19MEN1KMT2A
SCHEMBL27665548 0.69 BLM (0.40) ALDH1A1LMNAPOLBALOX5HPGD
SCHEMBL2399005 0.69 KEAP1 (0.53) ALDH1A1LMNASMN1; SMN2POLBALOX5
SCHEMBL25596197 0.68 LMNA (0.41) ALDH1A1LMNASMN1; SMN2POLBALOX5
SCHEMBL17490848 0.68 CHRNA7 (0.41) ALDH1A1LMNASMN1; SMN2AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME SENDA BIOSCIENCES INC (US) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME COMT, SNCA, PARK7 ALDH1A1 308/4885LMNA 4451/4885SMN1; SMN2 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.